Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response

 

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer1 (mCRC).

The new agreement is a conversion of two existing agreements with Hospital Del Mar (Barcelona, Spain) and inventors Dr. Bardelli and Dr. Arena from the University of Torino (Torino, Italy) in relation to two patent families of EGFR ectodomain mutations. Biocartis is entitled to sublicense the licensed rights to third parties.


Based on international guidelines[1], patients with mCRC are first tested on RAS-BRAF mutations for treatment with anti-EGFR targeted therapy. However, between 40-55% of these patients[2] develop resistance to this therapy, more specifically due to mutations arising in the RAS-BRAF genes, and as recently shown[3], also in the EGFR ectodomain[4]. To understand second and third line treatment options, it is therefore important to test if these mCRC patients develop these particular EGFR ectodomain mutations, since a triple negative RAS-BRAF-EGFR ectodomain result would mean that these patients could still benefit from certain targeted treatments[5].


The agreement includes the licensing of the EGFR S492R resistance mutation, which was the first EGFR ectodomain mutation detected by Dr. Montagut and Dr. Albanell (Hospital del Mar, Barcelona, Spain) in 2012[6] and subsequently licensed to Biocartis for commercialization on the Idylla(TM) system, more specifically in the solid biopsy Idylla(TM) NRAS-BRAF-EGFR S492R Mutation Assay (RUO)[7] as well as in the liquid biopsy Idylla(TM) ctNRAS-BRAF-EGFR S492R Mutation Assay (RUO7). Additional EGFR ectodomain mutations covered by the agreement were identified in a collaborative effort between the laboratories of Dr. Montagut and Dr. Bardelli and Dr. Arena in 2016.


Financial details of the agreement are not disclosed.

Note

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers fifteen oncology tests and two infectious disease tests in Europe. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?